Evidence map›Paper›PMID 37642856›Full record

ArticleDiscover oncology2023

Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.

Akihiro Sakai, Koji Ebisumoto, Hiroaki Iijima, Mayu Yamauchi, Takanobu Teramura, Aritomo Yamazaki, Takane Watanabe, Toshihide Inagi, Daisuke Maki, Kenji Okami

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Akihiro SakaiDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan. asakai-ygc@umin.ac.jp.ORCID http://orcid.org/0000-0002-1068-5061
Koji EbisumotoDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Hiroaki IijimaDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Mayu YamauchiDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Takanobu TeramuraDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Aritomo YamazakiDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Takane WatanabeDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Toshihide InagiDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Daisuke MakiDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Kenji OkamiDepartment of Otolaryngology, Head and Neck Surgery, Tokai University, School of Medicine, Isehara, Japan.
Tokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the clinical effectiveness of chemotherapy following immune checkpoint inhibitors (ICI). The association between inflammatory and nutritional factors and prognosis has also been investigated.

methodsWe retrospectively reviewed the medical records of recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC) patients who received chemotherapy following ICI therapy. The response rate and survival after chemotherapy, and nutritional and inflammatory factors, were examined.

resultsThe ICI before chemotherapy was nivolumab in 36 patients (70.6%) and pembrolizumab in 15 patients (29.4%). The chemotherapy regimens consisted of PTX in 32 patients (62.7%), PTX + Cmab in 9 (17.6%), and S1 in 10 (19.6%). The median overall survival (OS) was 20 months (95% CI 12-25), the estimated 12-month OS rate was 63.3%, the median progression-free survival (PFS) was 5 months (CI 4-6), and the 12-month PFS estimate was 8.9%. Univariate analysis significantly correlated Neutrophil-to-Lymphocyte Ratio (NLR), platelet-to-lymphocyte ratio (PLR), controlling nutritional status score (CONUT), and prognostic nutrition index (PNI) with OS and PFS. Additionally, these factors were significantly correlated with OS and PFS in the log-rank tests.

conclusionsChemotherapy following ICI is highly effective. There were no significant differences in the chemotherapy regimens. Inflammatory and nutritional factors may associate with patient prognosis after chemotherapy.

Indexed as

ChemotherapyDistant metastasisHead and neck cancerImmune checkpoint inhibitorPlatelet to lymphocyte ratioRecurrent

Identifiers

PMID37642856
PMCPMC10465419
OpenAlexW4386254840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.